XM does not provide services to residents of the United States of America.
P
P

Philips

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Philips Launches Duo Venous Stent System For Treatment Of Symptomatic Venous Outflow Obstruction

BRIEF-Philips Launches Duo Venous Stent System For Treatment Of Symptomatic Venous Outflow Obstruction June 12 (Reuters) - Koninklijke Philips NV PHG.AS : PHILIPS LAUNCHES DUO VENOUS STENT SYSTEM FOR TREATMENT OF SYMPTOMATIC VENOUS OUTFLOW OBSTRUCTION Source text for Eikon: ID:nGNX7Yd0Z3 Further company coverage: PHG.AS
P

Philips Successfully Prices Offering Of Notes For EUR 700 Million To Be Used For Repayment Of Existing Debt

BRIEF-Philips Successfully Prices Offering Of Notes For EUR 700 Million To Be Used For Repayment Of Existing Debt May 23 (Reuters) - Koninklijke Philips NV PHG.AS : PHILIPS SUCCESSFULLY PRICES OFFERING OF NOTES FOR EUR 700 MILLION TO BE USED FOR REPAYMENT OF EXISTING DEBT ISSUE PRICE FOR NOTES IS 98.257% WITH A COUPON OF 3.75%, RESULTING IN A YIELD OF 4.009%.
P

Column: In sleep apnea device litigation, who's getting the $1.1 billion settlement?

Column: In sleep apnea device litigation, who's getting the $1.1 billion settlement? The opinions expressed here are those of the author, a columnist for Reuters. By Jenna Greene May 23 (Reuters) - When Philips Respironics in 2021 recalled millions of devices for treating sleep apnea, the company warned users of potential ill effects including kidney and liver damage in connection with foam used in the machines.
P

Philips sues CPAP cleaning product maker, saying it should pay part of settlements

Philips sues CPAP cleaning product maker, saying it should pay part of settlements By Brendan Pierson May 13 (Reuters) - Philips PHG.AS has sued SoClean, a maker of ozone-based cleaning systems for breathing devices, in an effort to make it pay part of a $1.1 billion settlement Philips reached last month with people who say they were injured by Philips' recalled devices.
P

FDA Says Philips Respironics Recalls Trilogy Evo Continuous Ventilators

BRIEF-FDA Says Philips Respironics Recalls Trilogy Evo Continuous Ventilators May 13 (Reuters) - FDA: FDA: PHILIPS RESPIRONICS, INC. RECALLS TRILOGY EVO CONTINUOUS VENTILATORS DUE TO A SOFTWARE-RELATED POSSIBLE POWER MALFUNCTION FDA: FDA HAS IDENTIFIED THIS TRILOGY EVO CONTINUOUS VENTILATORS RECALL AS A CLASS I RECALL Further company coverage: PHG.
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.